144 ·Filed May 21, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001959173-26-003865
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The filing is routine and small in scale. Monitor for any subsequent large insider sales or changes in Flagship's ownership, but no immediate trading action warranted.

DirectionNeutral
Confidencemedium
Horizonimmediate
Final — all horizons settled through T+60d
MRNA ▲ +36.59% at T+60d
NEUTRAL call ✓ call won +36.59% · α vs SPY +32.56% · entry $47.19 → $64.46
Entry anchored
May 21, 2026
via day open
T+1d
-0.63%
call -0.63% · α -1.08%
$46.89
settled 4mo ago
T+5d
-0.30%
call -0.30% · α -2.15%
$47.05
settled 4mo ago
T+20d
+35.53%
call +35.53% · α +34.99%
$63.96
settled 3mo ago
T+60d
+36.59%
call +36.59% · α +32.56%
$64.46
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Flagship Pioneering, LLC, a major early investor in Moderna, filed a Form 144 to sell 9,263 shares of common stock with an aggregate market value of $433,880. The sale is tied to a cashless exercise of options expiring August 10, 2026. The relatively small share count (0.05% of market cap) suggests routine portfolio management rather than a negative signal.

Key Facts

  • Selling entity: Flagship Pioneering, LLC (early-stage venture capital investor and affiliate).
  • Proposed sale: 9,263 shares of Moderna common stock.
  • Aggregate market value: $433,879.85.
  • Shares sourced from cashless exercise of options granted on 08/10/2016, set to expire 08/10/2026.
  • Sale represents approximately 0.05% of Moderna's $19.1B market cap.

Financial Impact

Sale of $434k worth of stock, immaterial relative to $19.1B market cap.

dilution

Risk Factors

  • Insider selling could signal reduced conviction if it becomes a pattern.
  • Option expiration may prompt additional sales before August 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
30% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-003865
Document: 0001959173-26-003865-index.html0001959173-26-003865
Document: 0001959173-26-003865.txt0001959173-26-003865
18 reports for MRNA
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +14.15%Mar 5, 2026
Filters
Rows
Reports for MRNA — sortable, filterable
TypeNow
Sep 30, 2026
2d ago
ANALYST-DOWNGRADE
BEARISH ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
ANALYST-DOWNGRADE
BEARISH ★ 6/10
$148.87 $143.97▲ +3.29%▲ +2.14%$190.01 (−27.63%)
Aug 31, 2026
4w ago
Court Ruling
BEARISH ★ 6/10
$140.19 $140.33▼ −0.10%▼ −0.24%$190.01 (−35.54%)
Aug 25, 2026
5w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$158.83 $154.27▼ −2.87%▼ −2.33%$190.01 (+19.63%)
Aug 19, 2026
6w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$174.38 $149.66▼ −14.18%▼ −13.79%$190.01 (+8.96%)
Aug 5, 2026
8w ago
144
BEARISH ★ 6/10
$56.26 $63.67▼ −13.18%▼ −12.83%$190.01 (−237.77%)
Jul 31, 2026
9w ago
8-K
MIXED ★ 6/10
$54.82 $59.17▲ +7.94%▲ +4.42%$190.01 (+246.61%)
Jul 10, 2026
11w ago
3
NEUTRAL ★ 2/10
$67.01 $61.82▼ −7.75%▼ −6.96%$190.01 (+183.55%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$73.80 $67.44▼ −8.62%▼ −9.48%$190.01 (+157.47%)
Jun 18, 2026
15w ago
144
NEUTRAL ★ 2/10
$63.96 $59.75▼ −6.58%▼ −4.92%$190.01 (+197.08%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access